Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P David Mozley

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2004
Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agentAndrew B Newberg, Karl Plössl, P David Mozley, et al.
Journal of Parkinson'S Disease|March 3, 2020
Neurophysiological Biomarkers of Parkinson's DiseaseShani Waninger, Chris Berka, Marija Stevanovic Karic, et al.
Translational Oncology|February 21, 2012
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancerP David Mozley, Claus Bendtsen, Binsheng Zhao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2005
Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's diseaseRandel L Swanson, Andrew B Newberg, Paul D Acton, et al.
Nuclear Medicine and Biology|September 23, 2003
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNERMagnus Schou, Christer Halldin, Judit Sóvágó, et al.
Synapse (New York, N.Y.)|June 2, 2004
PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brainMagnus Schou, Christer Halldin, Judit Sóvágó, et al.
Academic Radiology|December 9, 2009
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarkerAndrew J Buckler, P David Mozley, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2014
Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volumeAndrea G Rockall, Norbert Avril, Raymond Lam, et al.
Nuclear Medicine Communications|July 8, 2005
Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primatesNicholas Seneca, Bengt Andree, Nils Sjoholm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 14, 2013
18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetryDean F Wong, Rikki Waterhouse, Hiroto Kuwabara, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2004
Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agentAndrew B Newberg, Karl Plössl, P David Mozley, et al.
Journal of Parkinson'S Disease|March 3, 2020
Neurophysiological Biomarkers of Parkinson's DiseaseShani Waninger, Chris Berka, Marija Stevanovic Karic, et al.
Translational Oncology|February 21, 2012
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancerP David Mozley, Claus Bendtsen, Binsheng Zhao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2005
Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's diseaseRandel L Swanson, Andrew B Newberg, Paul D Acton, et al.
Nuclear Medicine and Biology|September 23, 2003
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNERMagnus Schou, Christer Halldin, Judit Sóvágó, et al.
Synapse (New York, N.Y.)|June 2, 2004
PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brainMagnus Schou, Christer Halldin, Judit Sóvágó, et al.
Academic Radiology|December 9, 2009
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarkerAndrew J Buckler, P David Mozley, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2014
Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volumeAndrea G Rockall, Norbert Avril, Raymond Lam, et al.
Nuclear Medicine Communications|July 8, 2005
Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primatesNicholas Seneca, Bengt Andree, Nils Sjoholm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 14, 2013
18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetryDean F Wong, Rikki Waterhouse, Hiroto Kuwabara, et al.
Pageof 5